Attached files

file filename
EX-99.2 - EX-99.2 - Zynerba Pharmaceuticals, Inc.a17-15709_1ex99d2.htm
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc.a17-15709_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8—K

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 26, 2017

 


 

ZYNERBA PHARMACEUTICALS, INC.

(Exact Name of Issuer as Specified in Charter)

 


 

Delaware

 

001-37526

 

26-0389433

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

80 W. Lancaster Avenue, Suite 300

Devon, PA 19333

(Address of Principal Executive Offices)

 

(484) 581-7505

(Registrant’s Telephone Number, Including Area Code)

 


 

Check the appropriate box below if the Form 8—K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o       Soliciting material pursuant to Rule 14a—12 under the Exchange Act (17 CFR 240.14a—12)

 

o       Pre—commencement communications pursuant to Rule 14d—2(b) under the Exchange Act (17 CFR 240.14d—2(b))

 

o       Pre—commencement communications pursuant to Rule 13e—4(c) under the Exchange Act (17 CFR 240.13e—4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 



 

Item 7.01      Regulation FD Disclosure

 

On June 26, 2017, Zynerba Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the initiation of its ZYN001 Phase 1 clinical program to study the Company’s patent-protected pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

Item 8.01      Other Events

 

Attached as Exhibit 99.2 is a presentation that the Company will post on its website on June 26, 2017 and may use from time to time in presentations or discussions with investors, analysts and other parties.

 

Item 9.01      Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release, dated June 26, 2017.

99.2

 

Zynerba Pharmaceuticals, Inc. Investor Presentation.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 26, 2017

 

 

ZYNERBA PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Suzanne Hanlon

 

 

Name: Suzanne Hanlon

 

 

Title: Secretary, General Counsel and Vice President, Human Resources

 

3



 

EXHIBIT INDEX

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release, dated June 26, 2017.

99.2

 

Zynerba Pharmaceuticals, Inc. Investor Presentation.

 

4